Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03262935
Title SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (TULIP)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Byondis B.V.
Indications

breast cancer

Therapies

Capecitabine + Lapatinib

Trastuzumab Duocarmazine

Eribulin + Trastuzumab

Capecitabine + Trastuzumab

Trastuzumab + Vinorelbine

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL


No variant requirements are available.